Study S001973

Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of 36 Weeks of Treatment With NLY01 in Early-stage Parkinson's Disease

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT04154072
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE2
Masking: QUADRUPLE
Status: COMPLETED
Enrollment: 255
Start: 2020-02-27
Primary completion: 2023-02-14
Lead sponsor: Neuraly, Inc.
Conditions: Parkinson Disease
Interventions: DRUG:NLY01; DRUG:Vehicle
Results posted: FALSE
Individual participant data sharing: UNDECIDED

Registered primary outcomes

Change in Unified Parkinson's Disease Rating Scale in combined score of Parts II and III from baseline to 36 weeks [36 weeks]

Linked records (1)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0011719	Safety, tolerability, and efficacy of NLY01 in early untreated Parkinson's disease: a randomised, double-blind, placebo-controlled trial. McGarry A, The Lancet. Neurology	2024	Randomized trial	PMID 38101901 DOI	cites ClinicalTrials.gov:NCT04154072; registry reference DERIVED:38101901